Connection

Co-Authors

This is a "connection" page, showing publications co-authored by BONNIE S GLISSON and MERRILL S KIES.
Connection Strength

1.311
  1. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):67-73.
    View in: PubMed
    Score: 0.166
  2. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. Cancer. 2018 05 15; 124(10):2169-2173.
    View in: PubMed
    Score: 0.157
  3. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010 Jan 01; 28(1):8-14.
    View in: PubMed
    Score: 0.088
  4. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9.
    View in: PubMed
    Score: 0.071
  5. Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma. Clin Cancer Res. 2024 Nov 12.
    View in: PubMed
    Score: 0.062
  6. A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer. 2004 Mar 01; 100(5):991-8.
    View in: PubMed
    Score: 0.059
  7. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004 Feb 01; 10(3):944-6.
    View in: PubMed
    Score: 0.059
  8. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist. 2020 10; 25(10):e1457-e1463.
    View in: PubMed
    Score: 0.046
  9. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019 03 01; 30(3):471-477.
    View in: PubMed
    Score: 0.042
  10. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma. Head Neck. 2018 08; 40(8):1676-1684.
    View in: PubMed
    Score: 0.039
  11. Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas. Oncologist. 2018 05; 23(5):526-e49.
    View in: PubMed
    Score: 0.039
  12. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol. 2017 Dec; 77(6):1110-1113.e2.
    View in: PubMed
    Score: 0.038
  13. Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck. 2017 08; 39(8):1671-1679.
    View in: PubMed
    Score: 0.037
  14. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26; 7(17):23227-38.
    View in: PubMed
    Score: 0.034
  15. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015 May; 37(5):644-9.
    View in: PubMed
    Score: 0.032
  16. Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiat Oncol. 2013 Jan 29; 8:21.
    View in: PubMed
    Score: 0.028
  17. Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol. 2012 Dec; 130(12):1608-11.
    View in: PubMed
    Score: 0.027
  18. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63.
    View in: PubMed
    Score: 0.023
  19. A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2009 Jun; 32(3):274-9.
    View in: PubMed
    Score: 0.021
  20. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol. 2009 Apr 20; 27(12):1976-82.
    View in: PubMed
    Score: 0.021
  21. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):119-27.
    View in: PubMed
    Score: 0.020
  22. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys. 2009 Feb 01; 73(2):399-409.
    View in: PubMed
    Score: 0.020
  23. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer. 2006 Mar; 7(5):326-31.
    View in: PubMed
    Score: 0.017
  24. Neoadjuvant chemotherapy for squamous cell carcinoma of the oral tongue in young adults: a case series. Head Neck. 2005 Sep; 27(9):748-56.
    View in: PubMed
    Score: 0.016
  25. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer. 2005 Aug 01; 104(3):561-9.
    View in: PubMed
    Score: 0.016
  26. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer. 2004 Dec 01; 101(11):2567-73.
    View in: PubMed
    Score: 0.016
  27. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res. 2004 May 01; 10(9):2968-76.
    View in: PubMed
    Score: 0.015
  28. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1369-77.
    View in: PubMed
    Score: 0.015
  29. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer. 2004 Apr; 44(1):99-110.
    View in: PubMed
    Score: 0.015
  30. Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer. 2004 Mar 15; 100(6):1171-8.
    View in: PubMed
    Score: 0.015
  31. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer. 2003 Nov 15; 98(10):2214-23.
    View in: PubMed
    Score: 0.015
  32. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2002 Jul 15; 95(2):322-30.
    View in: PubMed
    Score: 0.013
  33. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 2002 Jul 15; 95(2):340-53.
    View in: PubMed
    Score: 0.013
  34. ZD1839 (Iressa) in non-small-cell lung cancer. Clin Lung Cancer. 2001 Aug; 3(1):27-32.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.